Jw Holdings Asset Resilience Ratio
Jw Holdings asset resilience ratio. Jw Holdings (096760) has an Asset Resilience Ratio of 1.56% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Jw Holdings fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Jw Holdings (2007–2024)
Asset resilience ratio of Jw Holdings from 2007 to 2024. This chart shows how Jw Holdings's Asset Resilience Ratio has changed over time. Read debt load of Jw Holdings for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Jw Holdings's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Jw Holdings.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩19.24 Billion | 1.56% |
| Total Liquid Assets | ₩19.24 Billion | 1.56% |
Asset Resilience Insights
- Limited Liquidity: Jw Holdings maintains only 1.56% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Jw Holdings Industry Peers by Asset Resilience Ratio
Compare Jw Holdings's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Jw Holdings Asset Resilience Ratio by Year (2007–2024)
Jw Holdings asset resilience ratio by year from 2007 to 2024. The table below shows the annual Asset Resilience Ratio data for Jw Holdings.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 2.41% | ₩30.14 Billion ≈ $20.43 Million |
₩1.25 Trillion ≈ $847.52 Million |
-4.44pp |
| 2023-12-31 | 6.85% | ₩80.61 Billion ≈ $54.62 Million |
₩1.18 Trillion ≈ $797.14 Million |
-2.00pp |
| 2022-12-31 | 8.85% | ₩102.48 Billion ≈ $69.45 Million |
₩1.16 Trillion ≈ $784.48 Million |
+3.47pp |
| 2021-12-31 | 5.39% | ₩57.41 Billion ≈ $38.91 Million |
₩1.07 Trillion ≈ $722.26 Million |
+0.34pp |
| 2020-12-31 | 5.04% | ₩56.44 Billion ≈ $38.25 Million |
₩1.12 Trillion ≈ $758.15 Million |
+4.05pp |
| 2019-12-31 | 0.99% | ₩12.36 Billion ≈ $8.38 Million |
₩1.24 Trillion ≈ $842.68 Million |
-0.80pp |
| 2018-12-31 | 1.79% | ₩22.83 Billion ≈ $15.47 Million |
₩1.28 Trillion ≈ $864.48 Million |
+0.58pp |
| 2017-12-31 | 1.21% | ₩16.40 Billion ≈ $11.12 Million |
₩1.35 Trillion ≈ $915.81 Million |
-2.93pp |
| 2016-12-31 | 4.15% | ₩49.63 Billion ≈ $33.64 Million |
₩1.20 Trillion ≈ $810.94 Million |
+3.89pp |
| 2015-12-31 | 0.26% | ₩2.76 Billion ≈ $1.87 Million |
₩1.08 Trillion ≈ $733.84 Million |
-0.03pp |
| 2014-12-31 | 0.28% | ₩2.93 Billion ≈ $1.98 Million |
₩1.04 Trillion ≈ $702.09 Million |
-0.10pp |
| 2013-12-31 | 0.38% | ₩3.84 Billion ≈ $2.60 Million |
₩1.01 Trillion ≈ $687.47 Million |
+0.07pp |
| 2012-12-31 | 0.31% | ₩3.29 Billion ≈ $2.23 Million |
₩1.08 Trillion ≈ $729.96 Million |
+0.01pp |
| 2011-12-31 | 0.29% | ₩3.20 Billion ≈ $2.17 Million |
₩1.09 Trillion ≈ $741.92 Million |
-0.17pp |
| 2010-12-31 | 0.46% | ₩3.41 Billion ≈ $2.31 Million |
₩736.86 Billion ≈ $499.36 Million |
-0.13pp |
| 2009-12-31 | 0.59% | ₩4.17 Billion ≈ $2.83 Million |
₩709.64 Billion ≈ $480.91 Million |
-1.76pp |
| 2008-12-31 | 2.35% | ₩15.08 Billion ≈ $10.22 Million |
₩642.09 Billion ≈ $435.13 Million |
-3.11pp |
| 2007-12-31 | 5.46% | ₩30.30 Billion ≈ $20.54 Million |
₩554.89 Billion ≈ $376.04 Million |
-- |
About Jw Holdings
JW Holdings Corporation, together with its subsidiaries, operates as a healthcare company in South Korea, the United States, Japan, China, and internationally. The company offers amino acid solutions, gastrointestinal agents, wound care, eye care, liver disease treatment, cold medicine, API, oral and topical analgesic, and other miscellaneous pharmaceutical products. It also offers hairdye, hair … Read more